Comparison of pharmacokinetic parameters of rituximab referring obtained in studies with a population approach
| Study . | Population . | Median age, y (range) . | Sex, male/female, n . | Clearance, mL/h . | Vdss, L . | Vc, L . |
|---|---|---|---|---|---|---|
| Ng et al17 | Rheumatoid arthritis | 55 (26-76) | 22/85 | 10.7 (3.4% CV) | N/M | 3.0 (2.1% CV) |
| Blasco et al11 | DLBLC | 51.5 (33-74) | 7/3 | 4.9 (73.9% CV) | 12 (12.2% CV) | 1.8 (12.9% CV) |
| Regazzi et al35 | Follicular lymphoma | N/M | 22 total | 5.1 (range, 3.8-8.1) | 4.5 (range, 2.6-5.3) | 1.8 (range, 1.6-2.1) |
| Present study | DLBLC | 69 (60-79) | 9/11 | 9.4 (range, 8.1-10.8) | 9.6 (range, 8.4-10.8) | 3.9 (3.5-4.3) |
| Study . | Population . | Median age, y (range) . | Sex, male/female, n . | Clearance, mL/h . | Vdss, L . | Vc, L . |
|---|---|---|---|---|---|---|
| Ng et al17 | Rheumatoid arthritis | 55 (26-76) | 22/85 | 10.7 (3.4% CV) | N/M | 3.0 (2.1% CV) |
| Blasco et al11 | DLBLC | 51.5 (33-74) | 7/3 | 4.9 (73.9% CV) | 12 (12.2% CV) | 1.8 (12.9% CV) |
| Regazzi et al35 | Follicular lymphoma | N/M | 22 total | 5.1 (range, 3.8-8.1) | 4.5 (range, 2.6-5.3) | 1.8 (range, 1.6-2.1) |
| Present study | DLBLC | 69 (60-79) | 9/11 | 9.4 (range, 8.1-10.8) | 9.6 (range, 8.4-10.8) | 3.9 (3.5-4.3) |
CV indicates coefficient of variation; and N/M, not mentioned.